Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Inhibitor Therapeutics, Inc. (INTI) had Consolidated Net Income/Loss of $-3.03M for the most recently reported fiscal year, ending 2023-12-31.
| Income Statement Financials | |
-- |
|
$-3.03M |
|
-- |
|
-- |
|
$3.40M |
|
$-3.40M |
|
$0.38M |
|
$-3.03M |
|
$-3.03M |
|
$-3.03M |
|
$-3.03M |
|
|
Consolidated Net Income/Loss |
$-3.03M |
$-3.03M |
|
$-3.40M |
|
$-3.40M |
|
171.95M |
|
171.95M |
|
$-0.02 |
|
$-0.02 |
|
| Balance Sheet Financials | |
$8.95M |
|
-- |
|
-- |
|
$8.95M |
|
$0.67M |
|
-- |
|
$3.00M |
|
$3.67M |
|
$5.28M |
|
$5.28M |
|
$5.28M |
|
172.02M |
|
| Cash Flow Statement Financials | |
$-2.70M |
|
-- |
|
$-0.41M |
|
$11.95M |
|
$8.84M |
|
$-3.11M |
|
$0.01M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
13.45 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-2.70M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-57.27% |
|
-57.27% |
|
-33.81% |
|
-57.27% |
|
$0.03 |
|
$-0.02 |
|
$-0.02 |
|